591772-85-9

Upstream product

• 591773-11-4 cyclo(-L-Am₇-D-Tyr(Me)-L-Ile-D-Pro-) 
• 591772-67-7 cyclo(-L-Ab₇-D-Tyr(Me)-L-Ile-D-Pro-) 
• 591772-75-7 S-(5-((3S,6R,9S,14aR)-9-((S)-sec-butyl)-6-(4-methoxybenzyl)-1,4,7,10-tetraoxotetradecahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecin-3-yl)pentyl)ethanethioate 
• 591772-49-5 Boc-L-Ab₇-D-Tyr(Me)-L-Ile-D-Pro-OBzl 
• 648929-44-6 Boc-L-Ab₇-D-Tyr(Me)-L-Ile-D-Pro-OH 

Downstream Products

• 591773-11-4 cyclo(-L-Am₇-D-Tyr(Me)-L-Ile-D-Pro-) 

Relevant academic research and scientific papers

Histone deacetylase inhibitors and process for producing the same

Compounds represented by formula (1) have strong inhibitory activity that is selective towards HDAC1 and HDAC4. Therefore, the compounds of the present invention are useful as pharmaceutical agents for treating or preventing diseases caused by HDAC1 and HDAC4.

Cyclic Tetrapeptides Bearing a Sulfhydryl Group Potently Inhibit Histone Deacetylases

(Equation presented) New inhibitors of histone deacetylase (HDAC) containing a sulfhydryl group were designed on the basis of the corresponding hydroxamic acid (CHAP31) and FK228. Their disulfide dimers and hybrids exhibited potent HDAC inhibitory activity in vivo with potential as anticancer prodrugs.